ALK Abello's EURneffy Preferred by 90% of Users Over Auto-Injectors
Event summary
- ALK Abello presented data at the 2026 AAAAI Annual Meeting showing 88% of participants preferred EURneffy over auto-injectors.
- The randomized crossover study involved 90 participants, with preference driven by ease of use, portability, and lack of stigma.
- EURneffy was rated significantly easier to carry and more likely to be kept on-person consistently compared to auto-injectors.
- Additional findings will be presented at future congresses throughout 2026 and beyond.
The big picture
ALK Abello's EURneffy represents a significant shift in anaphylaxis treatment, addressing long-standing barriers to auto-injector use. The preference for EURneffy highlights a broader industry trend towards more user-friendly, non-invasive medical devices. With regulatory approvals already secured in key markets, the company is well-positioned to capitalize on this growing demand for innovative allergy treatments.
What we're watching
- Market Adoption
- How quickly EURneffy can gain market share against established auto-injectors, given its preference among users.
- Regulatory Expansion
- Whether ALK Abello can secure additional regulatory approvals to expand EURneffy’s market reach beyond current regions.
- Clinical Impact
- The pace at which EURneffy’s ease of use and portability translate into improved anaphylaxis management outcomes.
Related topics